Medication info
Egliptin XR Extended Release Tablet 100/1000 Milligrams

Egliptin XR Extended Release Tablet 100/1000 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Vivozonn Pharmaceuticals Co., Ltd.
Appearance
Bright blue, oval-shaped, biconvex extended-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201938 · Approved 2022.05.11 · Insurance code 658204650

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, with gradual dose escalation. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the medicine did not dissolve completely and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablets once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Should Not Take This Medicine). 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start with their current doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Take This Medicine).

Ingredients

Manufacturer
Vivozonn Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes who have difficulties achieving blood sugar control with diet and exercise by administering sitagliptin and metformin together.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, with gradual dose escalation. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the medicine did not dissolve completely and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablets once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Should Not Take This Medicine). 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start with their current doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Take This Medicine).

Precautions

This medication, which contains sitagliptin and metformin, is a diabetes treatment, and there are several important precautions to take when using it. First, this medication can cause serious allergic reactions, albeit rarely, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck occur, it should be discontinued immediately and medical attention should be sought. Second, inflammation of the pancreas known as pancreatitis may occur, so if symptoms such as severe abdominal pain, vomiting, or fever appear, a doctor should be consulted immediately. Third, due to the metformin component, there is a risk of serious metabolic abnormality such as lactic acidosis, so if sudden fatigue, muscle pain, difficulty breathing, abdominal pain, or decreased consciousness occurs, emergency treatment should be sought immediately. Fourth, patients with impaired kidney function, severe infections, dehydration, or cardiovascular issues should not be administered this medication, and regular kidney function tests should be conducted, especially. Fifth, this medication is not recommended for use in women who are pregnant or breastfeeding, or in children under 18 years old. Sixth, while taking this medication, there is a risk of hypoglycemia, so one should eat regularly and avoid excessive alcohol intake or vigorous exercise, and caution is especially required when taken with other antidiabetic agents. Seventh, if undergoing surgery or receiving radiocontrast examinations, administration should be temporarily stopped and resumed only after kidney function has normalized. Finally, regular monitoring of blood sugar levels, kidney function, vitamin B12 levels, etc., should be performed during the use of this medication, and if any abnormal symptoms arise, medical consultation should be sought immediately.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infections
  • headache
Show 23 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • arthralgia with severe and disability
  • pemphigus-like eruption
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • hypoglycemia
  • hypoglycemia symptoms
  • anemia
  • peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is important to maintain the storage temperature between 1°C and 30°C at room temperature to safely retain the medication's efficacy.

Appearance and packaging

Appearance

Bright blue, oval-shaped, biconvex extended-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.